Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.54 |
| ▸ | TP53 | P04637 | 4/20 | 0.43 |
| ▸ | LMNA | P02545 | 4/20 | 0.43 |
| ▸ | THRB | P10828 | 3/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23474002 | 0.84 | MAPT (0.42) | MAPTTP53LMNANPC1RAB9A | |
| SCHEMBL5985206 | 0.79 | MAPT (0.53) | MAPTTP53LMNATHRBHTR2C | |
| SCHEMBL6989194 | 0.79 | FAAH (0.51) | MAPTLMNAKDM4EFAAH | |
| SCHEMBL19191161 | 0.76 | MAPT (0.50) | MAPTTP53LMNATHRBHTR2C | |
| SCHEMBL2710560 | 0.76 | PIM1 (0.41) | MAPTLMNARAB9AKDM4EFAAH | |
| SCHEMBL1759452 | 0.76 | MAPT (0.50) | MAPTTP53LMNATHRBHTR2C | |
| SCHEMBL5049374 | 0.76 | HTR3A (0.40) | MAPTTP53THRBNPC1RAB9A | |
| SCHEMBL1759343 | 0.76 | MAPT (0.54) | MAPTTP53LMNATHRBHTR2C | |
| SCHEMBL29652381 | 0.76 | MAPT (0.50) | MAPTTP53LMNATHRBHTR2C | |
| SCHEMBL2711462 | 0.76 | ESR1 (0.59) | MAPTLMNANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11814359-B2 | Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors | ASTRAZENECA AB (SE) | 2023-11-14 | — | — | US | disclosed |
| US-9920018-B2 | Fused heterocyclic compounds as ion channel modulators | GILEAD SCIENCES, INC. (US) | 2018-03-20 | — | — | US | disclosed |
| US-20170088527-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES, INC. | 2017-03-30 | — | — | US | disclosed |
| US-20160317504-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES, INC. | 2016-11-03 | — | — | US | disclosed |
| US-9416115-B2 | Fused heterocyclic compounds as ion channel modulators | GILEAD SCINECES, INC. (US) | 2016-08-16 | — | — | US | disclosed |
| US-20150175560-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES, INC. | 2015-06-25 | — | — | US | disclosed |
| US-7491729-B2 | 3-Substituted 3,4-dihydro-thieno[2,3-d]pyrimidin-4-one derivatives, production and use thereof | ABBOTT GMBH & CO. KG (DE) | 2009-02-17 | — | — | US | disclosed |
| EP-1572698-B1 | 3-SUBSTITUTED 3,4-DIHYDRO-THIENO¬2,3-D PYRIMIDINE-4-ONE-DERIVATIVES, PRODUCTION AND USE THEREOF | ABBOTT GMBH & CO KG (DE) | 2008-07-02 | — | — | EP | disclosed |
| US-20060142317-A1 | 3-Substituted 3,4-dihydro-thieno[2,3-d]pyrimidin-4-one derivatives, production and use thereof | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2006-06-29 | — | — | US | disclosed |
| EP-1572698-A1 | 3-SUBSTITUTED 3,4-DIHYDRO-THIENO[2,3-D]PYRIMIDINE-4-ONE-DERIVATIVES, PRODUCTION AND USE THEREOF | Abbott GmbH & Co. KG (DE) | 2005-09-14 | — | — | EP | disclosed |
| WO-2004055024-A1 | 3-SUBSTITUTED 3,4-DIHYDRO-THIENO[2,3-D]PYRIMIDINE-4-ONE-DERIVATIVES, PRODUCTION AND USE THEREOF | ABBOTT GMBH & CO. KG (DE) | 2004-07-01 | — | — | WO | disclosed |
| EP-0779281-B1 | ISOXAZOLES | SANKYO CO (JP) | 2003-10-29 | — | — | EP | disclosed |
| US-6096771-A | ISOXAZOLE DERIVATIVES EXHIBITING EXCELLENT TYPE B AND TYPE A MONOAMINE OXIDASE INHIBITORY ACTIVITIES, THEREFORE USEFUL FOR PREVENTING PARKINSON'S DISEASE, DEPRESSION AND ALZHEIMER'S DISEASE | SANKYO COMPANY, LIMITED (JP) | 2000-08-01 | — | — | US | disclosed |
| US-5965591-A | MONOAMINE OXIDASE INHIBITOR; FOR PROPHYLAXIS AND TREATING PARKINSON'S DISEASE, DEPRESSION AND ALZHEIMER'S DISEASE | SANKYO COMPANY, LIMITED (JP) | 1999-10-12 | — | — | US | disclosed |
| EP-0779281-A1 | ISOXAZOLES | SANKYO COMPANY LIMITED (JP) | 1997-06-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170088527-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | CACNA1A, KCNJ2, KCNH2 | MAPT 4473/4885TP53 3425/4885LMNA 527/4885 |
| US-20060142317-A1 | 3-Substituted 3,4-dihydro-thieno[2,3-d]pyrimidin-4-one derivatives, production and use thereof | HTR3C, DRD3, HTR4 | MAPT 4455/4885TP53 4590/4885LMNA 3682/4885 |
| US-11814359-B2 | Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors | DPP4, DPP7, DPEP1 | MAPT 4171/4885TP53 4778/4885LMNA 3873/4885 |
| US-20150175560-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | CACNA1A, KCNJ2, KCNH2 | MAPT 4473/4885TP53 3425/4885LMNA 527/4885 |
| US-20160317504-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | CACNA1A, KCNJ2, KCNH2 | MAPT 4473/4885TP53 3425/4885LMNA 527/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.